Wire · opportunities
FDA Approves RAS Inhibitor Daraxonrasib for Pancreatic Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 August 2026 · Fusion42 review
The FDA has approved daraxonrasib, the first RAS-targeted therapy for metastatic pancreatic ductal adenocarcinoma in adults who have had prior systemic therapy or are unsuitable for multiagent therapy, based on phase 3 trial results showing nearly doubled overall survival.
This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 16 Oct 2026.
◆ ◆ The Wire takeaway
You have a new US regulatory pathway opened for RAS-mutated pancreatic cancer that could reshape treatment standards and patient access. If your biotech develops targeted oncology therapies, daraxonrasib’s approval sharpens the urgency to push RAS-directed options forward.
◆ Coverage
48 sources · first reported 26 Aug 2026 · latest 16 Oct 2026
◆ Related on Wire
◆ Topics